PTC/SB/08s (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete If Known 10/662,820 Wute for form 1449A/PTO ABBRESTON NUMBER ORMATION DISCLOSURE September 16, 2003 FUMO DATE FIRE Named Inventor Koike et al. SEATEMENT BY APPLICANT Lo Be Assigned | (4) AR U/U 1089.041000171UM EXAMINE NAME (Use as many sheets as necessary) Attorney Docker Number 2 of Sheets

Exeminer	Cite No.	Occument Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*		Number-Kind Code ^{2 (# Kross)}	MM-DD-YYYY	Cited Document		
		US·				
		US-				
		US-			<u> </u>	
		US-				
		US-		paren.		
-		US-				
		US-	, por			
		US-	No.			
		US			·	
	 -	US-				
		US-			<u> </u>	
		US-				
	_	US-				
		US-				
		USA				
	1-	US-				
		US-				
	4	US-				

			FOREIGN PATENT D	OCUMENTS		
Exe mine r initial a*	Cite No."	Foreign Patent Document Country Code* Kind Code* (In known)	Publication Date MM-DD-YYYY	Name of Palentos or Applicant of Cited Document	Pages, Columns, Lines, Where Retevent Passages or Retevent Figures Appear	ī
M	- AAI	JP 06-305955	11-01-1994	Eisai Co. Ltd.		
11	ABI	JP 63-183921 A	08-01-1988	Takeda Chem Ind. Ltd.		
- U						
			·			
				·		

Examiner Signature	Date Considered	11/12/04
--------------------	--------------------	----------

"EXAMINER: Initial if reference considered, whether or not clistion is in conformance with M PEP 609. Draw line through clistion if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicants unique clistion designation number (optional)." See Minds Codes of USPTO Patent Documents at https://www.usprice.gov/mmw.ns/documents/. "Applicants unique clistion designation number (optional)." See Minds Codes of USPTO Patent Documents at https://www.ns/documents/. "Applicants unique of WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English tanguage Transaction is attached." All the properties symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English tanguage Transaction is stached." This collection of Information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an This collection of Information is required by 37 CFR 1.14. This collection is estimated to take 2 hours to complete, Including gathering, preparing, and submitting the application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, Including gathering, preparing, and submitting the application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandris, VA 22313-1450. DO reducing this burden, should be s

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Com	Complete If Known		
Substitute for form 1449B/PTO	Application Number	10/662,820		
E DEORMATION DISCLOSURE	Filing Date	September 16, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Koike et al.		
7 201 2	Art Unit	To Be Assigned / (//		
(Use as many sheets as necessary)	Examiner Name	HEN HEN		
Sheet of 2 Of 2	Attorney Docket Number	1089.0410001/TUM		

		NON PATENT LITERATURE DOCUMENTS	
ceminer	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T
A	AA2	""Comparison of Antitumor Activity of Vitamins K ₁ , K ₂ and K ₃ on Human Tumor Cells By Two (MTT and SRB) Cell Viability Assays," Felicia Y H. Wu et al., Life Sciences, Vol. 52 pp. 1797-1804, Pergamon Press 1993.	
	AB2	"Changes of Plasma Des-y-Carboxy Prothrombin Levels In Patients With Hepatocellular Carcinoma In Response to Vitamin K," Midori Furukawa et al., Cancer, Vol. 69, Number 1, pp. 31-38, J.B. Lippincott Company, Philadelphia, January 1, 1992.	
	AC2	"DES-y-Carboxy Prothrombin As A Useful Predisposing Factor for the Development of Portal Venous Invasion in Patients with Hepatocellular Carcinoma," Yukihiro Koike et al., Cancer, Vol. 91, Number 3, pp. 561-569, John Wiley & Sons, Inc., February 1, 2001.	
	AD2	"The Growth Inhibitory Effects of Vitamins K and Their Actions On Gene Expression," Ziqiu Wang et al., Hepatology, Vol. 22, pp. 876-882, September 1995.	
A	AE2	O'Neil, J.M. et al., The Merck Index Thirteenth Edition, Merck & Co., Inc., 2001 pg. 1787, Item 10082 on Vitamin K.	
Ψ	AF2	Randomized Prospective Study of Prevention-from Tumor Invasion-Into Portal Vein In 120	士
		Patients with Hepatocollular Caroinoma by Vitamin K Administration, http://ddw02.agora.com/planner/displayabstract:asp?presentarionid=31, July 8, 2002.	7
	AG2	38th Annual Meeting of Liver Cancer Study Group of Japan, Item 110, p. 135, Inhibitory Effect of Vitamin K Injection Against the Recurrence of Hepatocellular Carcinoma, published on May 13, 2002	~
1	AH2	Japanese Journal of Gastroenterology, Vol. 99 Supplement, March 20, 2002, Item 308, A Clinical Study of the Effects of Vitamin K in Inhibiting Recurrence of Hepatocellular Carcinoma	~
M	A12	ACTA Hepatologica Japonica, Vol. 43 Supplement (1) 2002, May 20, 2003, Item O-98, A Randomized Prospective Controlled Study by Vitamin K-II Injection for the Purpose of Preventing Portal Venous Invasion (PVI)	1

/	7	/		
Examiner Signature	1//	Date Considered	11/1	2/04
	-771			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Complete if Known 10/662,820 Application Number September 16, 2003 Filing Date First Named Inventor Koike et al. 1614 Art Unit **Examiner Name** Raymond J. Henley, III Attorney Docket Number 1089.0410001/MAC/DJN

Cite No.1	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
AJ2	Koike, Y. et al., "Randomized Prospective Study of Prevention from Tumor Invasion into Portal Vein in 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration," available online at: http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31 (April 11, 2002)	
	AJ2	Koike, Y. et al, "Randomized Prospective Study of Prevention from Tumor Invasion into Portal Vein in 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration," available online at: http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31

Date **Examiner** Considered Signature ·

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line/through citation if not in conformance and

EXAMINER: Initial it reference considered, whether or not clasticit is in continuous with MPEP 609. Draw imputibility is distincted in the information is applicant.

Applicant's unique clastion designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. Inis collection is estimated to take 2 nours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.